Showing results (351-360 of 372) with videos related to

Sort By:
Pageof 38
JHEP Reports : Innovation in Hepatology|January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Cerebral Cortex (New York, N.Y. : 1991)|October 3, 2017
Activity-Dependent Neuroplasticity Induced by an Enriched Environment Reverses Cognitive Deficits in Scribble Deficient MouseMuna L Hilal, Maité M Moreau, Claudia Racca, et al.
Toxins|December 22, 2023
ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite EnvenomingStefanie K Menzies, Raquel Arinto-Garcia, Fernanda Gobbi Amorim, et al.
Computational and Structural Biotechnology Journal|April 11, 2025
HELENA project: Driving innovation in high energy density Li-metal halide solid-state batteries for electric vehicles and aircraftsPedro López-Aranguren, Pierre Lannelongue, Javier Carrasco, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH studyIan Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
Vaccines|April 23, 2022
COVID-19 Vaccine Hesitancy among Arab AmericansMira H Kheil, Deepti Jain, Jamil Jomaa, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
JAMA Oncology|September 23, 2016
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh ScoreAndrew X Zhu, Ari David Baron, Peter Malfertheiner, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Pageof 38